To:  ALL PRINCIPAL INVESTIGATORS/NURSES/DATA MANAGERS

 

From: PROTOCOL SECTION

 

Date: MAY 31, 2019

 

RE: NRG-GY012 IMPENDING CLOSURE

PROTOCOL TITLE: A Randomized Phase II Study comparing Single-Agent Olaparib, Single-Agent Cediranib and the Combination of Cediranib/Olaparib in Women with Recurrent, Persistent or Metastatic Endometrial Cancer
NCI Version Date 04/18/2019

Please be aware that NRG-GY012 has accrued 97 of the targeted 120 patient goal. The accrual rate for this trial has been faster than anticipated. At the current rate of accrual it is expected to complete in 2-3 weeks. Please monitor accrual on the CTSU website before approaching a patient. A Closure notice will be broadcast in the near future but likely to be effective on or by June 21, 2019.

 



Twitter

Four Penn Center 1600 JFK Blvd. Suite1020 , Philadelphia, PA, 19103


Update Profile/Email Address